Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 30;6:24. doi: 10.1186/s13569-016-0064-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Response assessment after nivolumab. a Best responses; sarcoma subtypes and concomitant use of pazopanib are shown. b Swimmer plot in 24 patients who received at least four doses of nivolumab. Patients on pazopanib are indicated in bold on the Y axis with the correspondent histology. DC dedifferentiate chondrosarcoma; EpS epithelioid sarcoma; MC mesencymal chondrosarcoma; LPS liposarcoma; LMS leiomyosarcoma; ASPS alveolar soft part sarcoma; SS synovial sarcoma; IS intimal sarcoma; OS osteosarcoma; DSRCT desmoplastic small round cell tumor; MPNST malignant peripheral nerve sheet tumor; UPS undifferentiated pleomorphic sarcoma; RMS rhabdomyosarcoma. *Patient died